Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: Antagonist effects of SR 141716A1,2

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 2, 1998, Pages 697-703

  Vivian, Jeffrey A ^a   Kishioka, Shiroh ^a,b   Butelman, Eduardo R ^a,c   Broadbear, Jillian ^a   Lee, Katherine O ^a   Woods, James H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID RECEPTOR AGONIST; DIAMORPHINE; DRONABINOL; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; QUADAZOCINE; RIMONABANT;

ANALGESIA; ANIMAL CELL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BREATHING RATE; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; HEART RATE; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

ANALGESICS, OPIOID; ANIMALS; BENZENEACETAMIDES; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; HEART RATE; HEROIN; MACACA MULATTA; MORPHOLINES; NAPHTHALENES; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; PYRROLIDINES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RECEPTORS, OPIOID; RESPIRATORY MECHANICS; TETRAHYDROCANNABINOL;

EID: 0032443374     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Aceto MD, Scates SM, Lowe JA and Martin BR (1996) Dependence on delta-9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290-1295.
2. Compton DR, Aceto MD, Lowe J and Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR 141716A): Inhibition of delta-9-tetrahydrocannabinol-induced responses and apparent agonist affinity. J Pharmacol Exp Ther 277:586-594.
3. Chait LD and Burke KA (1994) Preference for high- versus low-potency marijuana. Pharmacol Biochem Behav 49:643-647.
4. Dykstra LA and Woods JH (1986) A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J Pharmacol Methods 15:263-269.
5. Estrada U, Brase DA, Martin BR and Dewey WL (1987) Cardiovascular effects of delta-9- and delta-9(11)-tetrahydrocannabinol and their interaction with epinephrine. Life Sci 41:79-87.
6. Fan F, Compton DR, Ward S, Melvin L and Martin BR (1994) Development of cross-tolerance between delta-9-tetrahydrocannabinol, CP 55940 and WIN 55212. J Pharmacol Exp Ther 271:1383-1390.
7. Fredericks AB, Benowitz NL and Savanapridi CY (1981) The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. J Pharmacol Exp Ther 216:247-253.
8. Herzberg U, Eliav E, Bennett GJ and Kopin IJ (1997) The analgesic effects of R(+)-WIN 55212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221:157-160.
9. Hine B (1985) Morphine and delta-9-tetrahydrocannabinol: Two-way cross tolerance for antinociceptive and heart-rate responses in the rat. Psychopharmacology (Berl) 87:34-38.
10. Hine B, Toreelio M and Gershon S (1977) Analgesic, heart rate, and temperature effects of delta-8-THC during acute and chronic administration to conscious rats. Pharmacology 15:63-72.
11. Howell LL, Bergman J and Morse WH (1988) Effects of levorphanol and several kappa-selective opioids on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther 245:364-372.
12. Johnstone RE, Lief PL, Kulp RA and Smith TC (1975) Combination of delta-9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics. Anesthesiology 42:674-684.
13. Lichtman AH and Martin BR (1996) Delta-9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) 126:125-1313.
14. Malit LA, Johnstone RE, Bourke DI, Kulp RA, Klein V and Smith TC (1975) Intravenous delta-9-tetrahydrocannabinol: Effects of ventilatory control and cardiovascular dynamics. Anesthesiology 42:666-673.
15. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV and Wiethe KE (1992) Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 12:750-758.
16. Matsuzaki M, Casella GA and Ratner M (1987) Delta-9-tetrahydrocannabinol: EEG changes, bradycardia and hypothermia in the rhesus monkey. Brain Res Bull 19:223-229.
17. Pugh G Jr, Abood ME and Welch SP (1995) Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta-9-THC in the spinal cord. Brain Res 689:157-158.
18. Pugh G Jr, Mason DJ Jr, Combs V and Welch SP (1997) Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP 55940 in the spinal cord. J Pharmacol Exp Ther 281:730-737.
19. Reche I, Fuentes JA and Ruiz-Gayo M (1996a) Potentiation of delta-9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of mu- and kappa-opioid receptors. Eur J Pharmacol 318:11-16.
20. Reche I, Fuentes JA and Ruiz-Gayo M (1996b) A role for central cannabinoid and opioid systems in peripheral delta-9-tetrahydrocannabinol-induced analgesia in mice. Eur J Pharmacol 301:75-81.
21. 3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 58:1239-1247.
22. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C, Soubrie P Breliere JC and Le Fur G (1995) Biochemical and pharmacological characterisation of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941-1947.
23. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G and Caput D (1994) SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
24. 35S]thio)triphosphate binding in rat brain membranes. Life Sci 59:59-668.
25. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R and Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227.
26. Stark P and Dews PB (1980) Cannabinoids. I. Behavioral effects. J Pharmacol Exp Ther 214:124-130.
27. Terranova JP, Storme JJ, Lafon N, Perio A, Rinaldi-Carmona M, Le Fur G and Soubrie P (1996) Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 126:165-172.
28. Tsou K, Patrick SL and Walker JM (1995) Physical withdrawal in rats tolerant to delta-9-tetrahydro cannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280:R13-R15.
29. Vidrio H, Sanchez-Salvatori MA and Medina M (1996) Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol 28:332-336.
30. Welch SP (1994) Blockade of cannabinoid-induced antinociception by naloxone benzoylhydrazone (NalBZH). Pharmacol Biochem Behav 49:929-934.
31. Welch SP, Dunlow LD, Patrick GS and Razdan RK (1995) Characterization of anandamide- and fluoranandamide-induced antinociception and cross-tolerance to delta-9-THC after intrathecal administration to mice: Blockade of delta-9-THC-induced antinociception. J Pharmacol Exp Ther 273:1235-1244.
32. Welch SP and Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262:10-18.
33. Wiley JL, Balster R and Martin B (1995b) Discriminative stimulus effects of anandamide in rats. Eur J Pharmacol 276:49-54.
34. Wiley JL, Barrett RL, Lowe J, Balster RL and Martin BR (1995c) Discriminative stimulus effects of CP 55940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669-676.
35. Wiley JL, Huffman JW, Balster RL and Martin BR (1995a) Pharmacological specificity of the discriminative stimulus effects of delta-9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend 40:81-86.
36. Wiley JL, Lowe JA, Balster RL and Martin BR (1995d) Antagonism of the discriminative stimulus effects of delta-9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.
37. Zacny JP and Chait LD (1992) Response to marijuana as a function of potency and breathhold duration. Psychopharmacology (Berl) 103:223-226.